Novellus

    OverviewSuggest Edit

    Novellus is an engineered cellular medicine company. It combines its patented gene editing and cell reprogramming technologies. The company serves patients with such diseases as AAT deficiency, Parkinson's, Crohn's disease, dystrophic epidermolysis bullosa, etc.
    TypePrivate
    Founded2015
    HQCambridge, MA, US
    Websitenovellus-inc.com
    Employee Ratings4.4

    Latest Updates

    Employees (est.) (Sept 2021)15(-6%)
    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Novellus Office Locations

    Novellus has an office in Cambridge
    Cambridge, MA, US (HQ)
    1035 Cambridge St #17b
    Show all (1)

    Novellus Financials and Metrics

    Summary Metrics

    Founding Date

    2015

    Novellus Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    92/100

    SecurityScorecard logo

    Novellus Online and Social Media Presence

    Embed Graph

    Novellus News and Updates

    Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition

    NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange Commission a registration statement on Form S-1 relating to the proposed public offering by certain selling s…

    Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics

    Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy

    Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics

    Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing t…

    Lam Research Corporation Announces Notice of Full Redemption of 2.625% Senior Convertible Notes Due 2041 of Novellus Systems, Inc.

    FREMONT, Calif., March 26, 2021 (GLOBE NEWSWIRE) -- Lam Research Corporation (Nasdaq: LRCX) today announced that it has issued a notice of redemption, on behalf of its subsidiary Novellus Systems, Inc. (“Novellus”), for all of the 2.625% Senior Convertible Notes due 2041 issued by Novellus (CUSIP …

    Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions

    CAMBRIDGE, Mass., Oct. 13, 2020 /PRNewswire/ -- Novellus Therapeutics ("Novellus"), an engineered cellular medicines company, announced today that it has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to NoveCite, Inc., a newly formed subsidiary of Citius...

    Novellus Frequently Asked Questions

    • When was Novellus founded?

      Novellus was founded in 2015.

    • How many employees does Novellus have?

      Novellus has 15 employees.

    • Who are Novellus competitors?

      Competitors of Novellus include Nuclera, Editas Medicine and Creyon Bio.

    • Where is Novellus headquarters?

      Novellus headquarters is located at 1035 Cambridge St #17b, Cambridge.

    • Where are Novellus offices?

      Novellus has an office in Cambridge.

    • How many offices does Novellus have?

      Novellus has 1 office.